	US 12,447,208 B2
	Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses
Baiyong Li, Guangdong (CN); Yu Xia, Guangdong (CN); Zhongmin Wang, Guangdong (CN); Peng Zhang, Guangdong (CN); and Xinghua Pang, Guangdong (CN)
Assigned to AKESO BIOPHARMA, INC., Guangdong (CN)
Filed by AKESO BIOPHARMA, INC., Guangdong (CN)
Filed on Mar. 15, 2022, as Appl. No. 17/695,592.
Application 17/695,592 is a continuation of application No. 16/562,236, filed on Sep. 5, 2019, granted, now 11,291,720.
Application 16/562,236 is a continuation of application No. 15/500,744, granted, now 10,449,251, issued on Oct. 22, 2019, previously published as PCT/CN2015/085721, filed on Jul. 31, 2015.
Claims priority of application No. 201410377352.9 (CN), filed on Aug. 1, 2014.
Prior Publication US 2023/0064544 A1, Mar. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); C12N 5/10 (2006.01); C12N 15/63 (2006.01); G01N 33/577 (2006.01)

CPC A61K 39/39541 (2013.01) [A61K 39/395 (2013.01); C07K 16/28 (2013.01); C07K 16/2896 (2013.01); C07K 19/00 (2013.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01); G01N 33/577 (2013.01)]

14 Claims

1. A method of reducing or inhibiting CTLA4 activity comprising administering to cells a monoclonal antibody or antigen binding fragment thereof that binds to human CTLA4, comprising a heavy chain variable region and a light chain variable region, wherein

(a) the heavy chain variable region comprises:

an HCDR1 comprising the amino acid sequence of SEQ ID NO: 27,

an HCDR2 comprising the amino acid sequence of SEQ ID NO: 28, and

an HCDR3 comprising the amino acid sequence of SEQ ID NO: 29; and

(b) the light chain variable region comprises:

an LCDR1 comprising the amino acid sequence of SEQ ID NO: 30,

an LCDR2 comprising the amino acid sequence of SEQ ID NO: 31, and

an LCDR3 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 33, or SEQ ID NO: 34.